Floatz logo

Capecitabine

BRCA1 Mutation Carrier

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the BRCA1 Mutation Carrier cohort.

Asset / SponsorPhaseRating
Olaparib
VA Office of Research and Development
Phase 3BB
Carboplatin
VA Office of Research and Development
Phase 2BB
Letrozole
UNICANCER
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
University Health Network, Toronto
Phase 2/3BB
Veliparib
AbbVie
Phase 2BB

View all 26 →

Same molecule, other indications

Capecitabine is also rated in:

Locally Advanced Rectal CancerDormant
BBB
Indicative ·
75 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →
rectal carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →